A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers

Clinical and Experimental Nephrology

Volumn 21, Issue 3, 2017, Pages 407-416

  Johansson, Susanne ^a   Rosenbaum, David P ^b   Knutsson, Mikael ^a   Leonsson Zachrisson, Maria ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b Ardelyx Inc   (United States)

Author keywords

Chronic kidney disease; NHE3 protein; Phosphate absorption; Sodium absorption; Sodium, dietary; Tenapanor

Indexed keywords

BICARBONATE; CHLORIDE; CREATININE; PHOSPHORUS; SODIUM; TENAPANOR; GASTROINTESTINAL AGENT; ISOQUINOLINE DERIVATIVE; SLC9A3 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN 3; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CAUCASIAN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; FLUID INTAKE; FOLLOW UP; HEADACHE; HUMAN; JAPANESE (PEOPLE); LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHOSPHATE INTAKE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; SODIUM URINE LEVEL; TREATMENT DURATION; URINE SAMPLING; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FECES; INTESTINE; INTESTINE ABSORPTION; JAPAN; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FECES; FEMALE; GASTROINTESTINAL AGENTS; HEALTHY VOLUNTEERS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; ISOQUINOLINES; JAPAN; MALE; MIDDLE AGED; PHOSPHORUS; SODIUM; SODIUM-HYDROGEN EXCHANGER 3; SULFONAMIDES; YOUNG ADULT;

EID: 84976500756     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-016-1302-8     Document Type: Article

References (33)

1. + exchange. Annu Rev Physiol. 2005;67:411–43.
2. + exchanger 3 (NHE3) activity in NHE regulatory factor 1 (NHERF1) adaptor protein-deficient mice. Pflugers Arch. 2009;457:1079–91.
3. Orlowski J, Kandasamy RA, Shull GE. Molecular cloning of putative members of the Na/H exchanger gene family. cDNA cloning, deduced amino acid sequence, and mRNA tissue expression of the rat Na/H exchanger NHE-1 and two structurally related proteins. J Biol Chem. 1992;267:9331–9.
4. Tse CM, Brant SR, Walker MS, Pouyssegur J, Donowitz M. Cloning and sequencing of a rabbit cDNA encoding an intestinal and kidney-specific Na+/H+ exchanger isoform (NHE-3). J Biol Chem. 1992;267:9340–6.
5. + uptake in humans. Sci Transl Med. 2014;6:227ra36.
6. Labonté ED, Carreras CW, Leadbetter MR, Kozuka K, Kohler J, Koo-McCoy S, et al. Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J Am Soc Nephrol. 2014;26:1138–49.
7. Rosenbaum D, Johansson S, Carlsson B, Spencer AG, Stefánsson B, Knutsson M, et al. Tenapanor, a minimally absorbed NHE3 inhibitor, reduces dietary phosphorus absorption in healthy volunteers (presentation FR-OR112). J Am Soc Nephrol. 2014;25:72A.
8. Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation. 2011;123:1138–43.
9. Humalda JK, Navis G. Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease. Curr Opin Nephrol Hypertens. 2014;23:533–40.
10. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119:671–9.
11. Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126:2880–9.
12. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.
13. Gross P, Six I, Kamel S, Massy ZA. Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification. Circ J. 2014;78:2339–46.
14. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10:268–78.
15. Japanese Society of Nephrology. Evidence-based clinical practice guideline for CKD 2013. Clin Exp Nephrol. 2013;18:346–423.
16. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–4.
17. + balance. Cell Metab. 2013;17:125–31.
18. Lee MJ, Doh FM, Kim CH, Koo HM, Oh HJ, Park JT, et al. Interdialytic weight gain and cardiovascular outcome in incident hemodialysis patients. Am J Nephrol. 2014;39:427–35.
19. Kayikcioglu M, Tumuklu M, Ozkahya M, Ozdogan O, Asci G, Duman S, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant. 2009;24:956–62.
20. Maduell F, Navarro V. Dietary salt intake and blood pressure control in haemodialysis patients. Nephrol Dial Transplant. 2000;15:2063.
21. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;76:S1–130.
22. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34–8.
23. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770–9.
24. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;22:2909–16.
25. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:337–414.
26. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12:1640–4.
27. Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Stefansson BV, Rydén-Bergsten T, Greasley PJ, et al. Effect of tenapanor on interdialytic weight gain in patients on hemodialysis. Clin J Am Soc Nephrol. 2016. doi:10.2215/CJN.09050815.
28. Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M, Johansson S, Knutsson M, et al. Tenapanor, an NHE3 inhibitor, reduces serum phosphate in patients with CKD Stage 5D and hyperphosphatemia. J Am Soc Nephrol. 2015;26:30.
29. Stefansson BV, Rosenbaum DP, Greasley PJ, Leonsson-Zachrisson M, Langkilde A-M. A phase 2 study on the effect of tenapanor on albuminuria in patients with T2DM and CKD. J Am Soc Nephrol. 2015;26:239A.
30. Eutamene H, Charmot D, Navre M, Bueno L. Visceral antinociceptive effects of RDX5791, a first-in-class minimally systemic NHE3 inhibitor on stress-induced colorectal hypersensitivity to distension in rats. Gastroenterology. 2011;140:S-57–8.
31. Ardelyx. A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of AZD1722 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). Available from: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01923428. Accessed 14 March 2016.
32. Ardelyx. A 26-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tenapanor for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). Available from: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02686138. Accessed 22 April 2016.
33. Chey WD, Lembo AJ, Phillips JA, Rosenbaum DP. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 12-week, double-blind, placebo-controlled, randomized phase 2b trial. Gastroenterology. 2015;148:S-191–2.